DARVON COMPOUND-65 pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory	⤷ Get Started Free	Hg\|d@Dq]@\bbbbfJSSimUSTs@@	⤷ Get Started Free
ChemBridge	⤷ Get Started Free	5216007	⤷ Get Started Free
Sigma-Aldrich	⤷ Get Started Free	C0750_SIAL	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 1, 2025

Introduction

The procurement of high-quality active pharmaceutical ingredients (APIs) remains a critical component of pharmaceutical manufacturing, impacting product efficacy, safety, and regulatory compliance. Darvon Compound-65, a historically recognized formulation containing propoxyphene derivatives, has garnered attention within the pharmaceutical landscape for its analgesic properties. Although its use has diminished internationally due to safety concerns, understanding API sourcing for products associated with Darvon is relevant for legacy manufacturing, research, or regulatory adherence.

This article explores the sources of bulk APIs specific to Darvon Compound-65, examining the global landscape, regulatory considerations, key chemical suppliers, and the implications for pharmaceutical manufacturers and stakeholders.

Overview of Darvon Compound-65 and Its API Components

Darvon Compound-65 traditionally contains a combination of phenylpropanolamine, acetaminophen, and propoxyphene derivatives, primarily focused on analgesic and antitussive effects. The active ingredient—propoxyphene—has been withdrawn or restricted in many markets due to safety issues, especially related to cardiotoxicity.

Key API Components Include:

Propoxyphene (and its derivatives): The principal opioid analgesic.
Acetaminophen (Paracetamol): Analgesic and antipyretic.
Other excipients or co-ingredients: Not APIs but relevant for formulation considerations.

Since the API sourcing predominantly revolves around propoxyphene, this article emphasizes its procurement, along with considerations for other API components relevant to Darvon formulations.

Global API Manufacturing and Sourcing Landscape

1. Origin of Propoxyphene APIs

Propoxyphene was initially synthesized and marketed globally by major pharmaceutical firms in the mid-20th century. As safety concerns mounted, regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) revoked approval or placed severe restrictions on its use, which impacted API manufacturing and distribution.

Today, the primary sources for propoxyphene APIs are limited because:

Market discontinuation: Several manufacturers have ceased production due to safety and legal issues.
Regulatory restrictions: Many countries have banned or suspended marketing authorization, affecting API availability.
Legacy stockpiles: Some manufacturers maintain stocks for compounded or specialized use, especially in jurisdictions where restrictions are less strict.

2. Leading API Suppliers in the Global Pharmaceutical Market

Despite anticipated reductions in API production, a handful of companies continue to manufacture and supply propoxyphene and related APIs for research, compounding, or legacy products:

Chinese API Manufacturers: China remains the dominant supplier of bulk APIs, including older opioids like propoxyphene. Companies such as Zhejiang NHU Pharmaceutical Co. and Zhejiang Huahai Pharmaceuticals have facilities capable of producing APIs, including legacy compounds, subject to regulatory compliance.
Indian API Manufacturers: India hosts numerous API producers with the capacity for complex chemical synthesis, including APIs for discontinued drugs. Firms such as Aarti Drugs and Hetero Labs possess production lines capable of manufacturing opioids, subject to regulatory restrictions.
Eastern European and Other Manufacturers: Some European manufacturers specialized in older APIs, but many have phased out production due to safety concerns.

3. Regulatory Status and Impact on API Sourcing

The legal status of propoxyphene varies:

In the United States, the FDA withdrew approval for Darvon and Darvocet (which contained propoxyphene) in 2010 due to cardiotoxicity risks, effectively eliminating legal API procurement for commercial purposes ([1]).
In other jurisdictions such as some Latin American, African, or Asian countries, regulations are more permissive, enabling continued use and API procurement primarily for compounding, research, or legacy formulations.
Implication: Buyers must verify local regulations before sourcing APIs; cross-border regulation discrepancies can lead to legal and safety challenges.

Quality and Regulatory Considerations in API Sourcing

The integrity of APIs influences drug safety and efficacy. When sourcing APIs for Darvon Compound-65, especially existing or legacy formulations, the following factors must be prioritized:

Good Manufacturing Practices (GMP) Compliance: Ensures API quality, consistency, and safety.
Chemical purity and potency: APIs should meet pharmacopeial standards (USP, EP, JP).
Traceability and Certification: Certificates of Analysis (CoA), Certificates of Origin, and regulatory documentation affirm authenticity.
Supplier Audits: Conduct rigorous assessments of manufacturing facilities, especially when sourcing from regions with variable regulatory oversight.

Note: Many regulatory agencies have classified APIs for discontinued drugs under specific import/export restrictions, necessitating careful due diligence.

Key API Suppliers for Darvon Compound-65

Supplier	Location	API Offerings	Notes
Zhejiang NHU Pharmaceutical	China	Propoxyphene APIs	Capable of bulk API manufacturing, with GMP certification.
Aarti Drugs	India	Opioid APIs, including legacy APIs	Experienced in regulatory compliance for exports.
Zhejiang Huahai Pharmaceuticals	China	Various APIs, including opioids	Limited publicly available info about older APIs.
Dr. Reddy’s Laboratories	India	Opioids and analgesics APIs	Quality-centric supplier compliant with international standards.

Note: Due to the specific legal restrictions on propoxyphene, many suppliers focus on research-grade or pharmacopeial-grade APIs. Large pharmaceutical companies are less likely to produce or export propoxyphene APIs unless for specific, legally permissible purposes.

Supply Chain Challenges and Ethical Considerations

The sourcing of APIs for Darvon Compound-65 faces significant hurdles:

Legal and regulatory restrictions: Limited markets for certain APIs due to safety concerns.
Quality assurance issues: Variability in manufacturing standards across suppliers.
Market scarcity: Few suppliers maintain stock, especially following the withdrawal from major markets.
Risks of misuse or diversion: Opioid APIs are tightly controlled to prevent abuse.

Ethical considerations include ensuring that API sourcing complies with regulatory standards, supports legitimate research, and aligns with global efforts to minimize opioid misuse.

Future Outlook

The pharmacovigilance landscape continues to influence API supply in this category. While legacy APIs like propoxyphene are increasingly phased out, there remains a niche market for research, forensic, or legacy medicinal use. Suppliers adapting to these needs focus on compliance, traceability, and quality assurance.

Regulatory shifts—such as strengthened controls on opioids—may further restrict or eliminate API manufacturing and distribution for Darvon-related compounds. Stakeholders should monitor regulatory developments in key markets.

Key Takeaways

Limited API sources: Due to safety concerns, propoxyphene API manufacturing has significantly declined, with most supplies restricted to research or legacy uses.
Regional disparities: China and India remain primary sources, but regulatory restrictions complicate procurement.
Quality and compliance: Only GMP-certified suppliers should be considered, with thorough documentation.
Regulatory vigilance: Sourcing must adhere to local and international regulations, especially given the drug’s withdrawal status in major markets.
Strategic sourcing: Stakeholders must verify supplier credibility, maintain compliance, and evaluate alternative APIs where appropriate.

FAQs

1. Why is the availability of propoxyphene APIs limited globally?
Due to safety concerns—including cardiotoxicity—regulatory agencies in many countries have withdrawn or restricted approval of propoxyphene, leading to decreased manufacturing and distribution of its APIs.

2. Can APIs related to Darvon Compound-65 be legally imported for research purposes?
Yes, in jurisdictions where regulatory agencies permit research or forensic use, APIs can be legally imported with proper permits and documentation. However, strict compliance with import/export regulations is mandatory.

3. What quality standards should be considered when sourcing APIs for legacy formulations like Darvon Compound-65?
APIs should meet pharmacopeial standards (USP, EP, JP), have quality certificates, and originate from GMP-certified facilities to ensure safety and consistency.

4. Are there alternative sources of APIs for analgesic compounds similar to Darvon?
Yes, several non-opioid analgesic APIs are available, but they serve different therapeutic purposes. For opioid APIs like propoxyphene, options are increasingly limited due to regulatory bans.

5. What future trends could impact API sourcing for old opioid compounds?
Regulatory tightening, increased control over opioid APIs, and global efforts to combat misuse are likely to further restrict API production, impacting legacy formulations’ supply chains.

References

[1] FDA. "FDA Withdrawal of Approval of Darvon and Darvocet." 2010.
(https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warnings-unappealed-approval-approval-withdrawn-darvon-and-darvocet)

Bulk Pharmaceutical API Sources for DARVON COMPOUND-65